Medpace Holdings Inc
NASDAQ:MEDP
Net Margin
Medpace Holdings Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Medpace Holdings Inc
NASDAQ:MEDP
|
9.3B USD |
19%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
155B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
143.8B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.5T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.5B CHF |
10%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.7B USD |
18%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
195.8B CNY |
27%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.6B USD |
9%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.8B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.3B EUR |
7%
|
Medpace Holdings Inc
Glance View
Medpace Holdings Inc., a name renowned in the clinical research sector, operates at the heart of the drug development process. Founded in 1992 by Dr. August Troendle, Medpace carved a niche for itself as a full-service clinical contract research organization (CRO). The essence of its operation lies in managing the complex journey of bringing new pharmaceuticals and medical devices from conception through to approval. Medpace partners with various biopharmaceutical companies to design, conduct, and oversee clinical trials, aligning with regulatory requirements to ensure these products are safe and effective. The company stands out by offering a comprehensive suite of services, including strategic consulting, project management, and the integration of cutting-edge technologies—a holistic approach that often distinguishes it from competitors. The engine driving Medpace’s profitability is its model of operational excellence fueled by its disciplined and integrated approach. The company generates revenue primarily from the contracts it secures with sponsors for conducting each phase of clinical trials. By closely collaborating with its clients, Medpace ensures tailored solutions that operate under specified timelines and budgets, enhancing client retention and attracting new business. What truly underlines Medpace’s financial success is its ability to deliver high-quality results, evidenced by robust data captured during trials and the attainment of key endpoints. This reputation for quality not only nurtures client trust but also consolidates Medpace's standing as a pivotal player in the CRO industry, securing a sustainable revenue stream and ongoing growth in a competitive landscape.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Medpace Holdings Inc's most recent financial statements, the company has Net Margin of 19.3%.
You don't have any saved screeners yet